Dyadic International reports a 40% reduction in transferrin costs as it shifts toward commercial operations and seeks non-dilutive funding.
Dyadic International (DYAI) announced a 40% reduction in transferrin production costs during Q2 2026, highlighting progress in manufacturing efficiency. The company attributed the improvement to operational shifts and performance data-driven optimizations as it transitions from development to commercial sales.
Management noted increased product shipments, customer evaluations, and initial sales, alongside distribution expansion. The cost reduction aligns with efforts to secure non-dilutive capital amid a going concern disclosure, signaling financial strategy adjustments.
The company’s focus on commercialization and cost control reflects broader industry trends toward sustainable scaling in biopharmaceutical production.